Table 2. Summary of survival data for progression-free and overall survival according CTC count and immunohistochemical subtype.
| |
|
|
PFS | OS | ||||
|---|---|---|---|---|---|---|---|---|
| Subgroup | CTC < or ⩾5 | All | Events | Median survival (months) | Log-rank P-value | Events | Median survival (months) | Log rank P-value |
| All |
<5 |
84 |
52 |
17.6 (14.7–20.5) |
<0.001 |
21 |
NR |
<0.001 |
| |
⩾5 |
70 |
55 |
9.2 (5.8–12.6) |
|
35 |
26.3 (16.7–35.9) |
|
| Luminal A |
<5 |
27 |
17 |
18.5 (15.1–21.9) |
0.023 |
4 |
NR |
0.003 |
| |
⩾5 |
29 |
22 |
9.5 (4.8–14.2) |
|
15 |
21.0 (13.1–28.9) |
|
| Luminal B–HER2-negative |
<5 |
19 |
14 |
16.6 (8.7–24.5) |
0.051 |
6 |
NR |
0.057 |
| |
⩾5 |
10 |
8 |
5.0 (0.1–10.0) |
|
5 |
26.3 (0.1–56.0) |
|
| Luminal B–HER2-positive |
<5 |
19 |
10 |
17.6 (10.7–24.5) |
0.301 |
5 |
NR |
0.382 |
| |
⩾5 |
16 |
12 |
11.7 (9.1–14.3) |
|
7 |
31.3 (25.8–36.8) |
|
| HER2-positive (non-luminal) |
<5 |
7 |
4 |
19.0 (10.0–28.0) |
0.311 |
0 |
NR |
0.197 |
| |
⩾5 |
7 |
5 |
10.1 (0.3–19.9) |
|
1 |
NR |
|
| Triple negative |
<5 |
8 |
7 |
13.4 (9.2–17.6) |
0.009 |
6 |
25.4 (16.0–34.8) |
0.019 |
| ⩾5 | 8 | 8 | 2.1 (0.7–3.5) | 7 | 2.8 (0.1–9.3) | |||
Abbreviations: CTC=circulating tumour cells; OS=overall survival; PFS=progression-free survival. Bold values indicate significant P-values (P<0.05).